- All cancer types
- Brain tumor
- Breast cancer
- Cervical cancer
- Childhood cancer
- Colon cancer
- Endometrial cancer
- Kidney cancer
- Lung cancer
- Multiple myeloma
- Ovarian cancer
- Pancreatic cancer
- Prostate cancer
- Skin cancer
- Stomach cancer
- Testicular cancer
Blog: Lung cancer
We presented the interim analysis of a randomised clinical trial, showcasing improved patient quality of life, and illustrating the patient experience via real world data.
CareAcross at ASCO 23: Using Patient-Reported Outcomes (PROs) to understand Cancer-Related Thrombosis
Explore the power of patient-reported outcomes (PROs) in understanding cancer-related thrombosis. CareAcross abstract from the American Society of Clinical Oncology (ASCO) congress in Chicago.
Two abstracts featuring real world data presented at WCLC 22: Comparing side-effects between past/current smokers and never smokers; and examining differences in toxicity among platinum-based combinations.
Did you know that 10-20% of lung cancer patients have never smoked? Is it worth it to quit smoking after a lung cancer diagnosis? Some of these myths may surprise you.
The annual congress of American Society of Clinical Oncology is the most important meeting of oncologists worldwide, with about 35,000 delegates. This year, in lung cancer and mesothelioma, several developments were announced with interest to patients.
Professor Håkan Mellstedt is a medical oncologist at the Cancer Center Karolinska in Sweden, with extensive clinical and academic experience. In this article, Prof. Mellstedt, also a member of our Scientific Committee, explains the basics of immunotherapy and key research being conducted across cancer types.
What is more difficult, fighting cancer yourself or watch your child fight it? Are we the ones to blame for the rise of cancer nowadays? Is there a link between baldness and prostate cancer? What do you think?
“A bad attitude is like a flat tire. If you don’t change it you’ll never go anywhere.” Some patients have gotten this 100% right, and they apply this principle both during and after their treatments. And if you like quotes, here’s one to write down: “Fear isn’t real, it’s all in your head”.
Federico Cappuzzo is an expert in personalized treatment for lung cancer. We recently asked him to address important issues for patients’ lung cancer screening and treatment.
Targeted therapy is a new development in oncology, which attacks cancer cells but does less damage to normal cells. Professor Tony Mok, a member of the CareAcross Scientific Committee, is an expert in targeted treatments for lung cancer. In this article, he answers 4 important questions relevant to anyone affected by lung cancer.
Dr. Enriqueta Felip, member of the CareAcross Scientific Committee, is a renowned expert in lung cancer. She holds a PhD in Medical Oncology, and has broad experience in cancer research as well as clinical practice. We recently asked her a few questions on lung cancer, and here are her responses.
Lung cancer is the most deadly cancer worldwide, claiming the lives of more than 1.5 million people annually. Our Chief Medical Officer attended the 2014 Congress of the European Society for Medical Oncology (ESMO) and summarizes the key findings.
A session at the 2014 ASCO meeting focused on targeted adenocarcinoma treatment for specific genetic mutations-a promising option for some lung cancer patients.
A routine examination showed throat cancer. Another tumor, in the left lung, made her fear she wouldn’t make it. 5 years later, she tells us how she made it.
At the European Lung Cancer Conference, new information on lung cancer incidence, key factors and genetic mutations were discussed. We present the highlights.
Stereotactic body radiotherapy has been found effective for early stage lung cancer patients who cannot undergo surgery due to risk from other health issues. Our Chief Medical Officer provides an analysis of the recent clinical findings.
Adenocarcinoma is the most common type of non-small cell lung cancer. Our Chief Medical Officer explains the benefits from the latest research on targeted drugs.